SCHOTT and Serum Institute announce JV for pharma packaging
Serum buys 50 per cent stake in Indian joint venture of SCHOTT Kaisha
Serum buys 50 per cent stake in Indian joint venture of SCHOTT Kaisha
Domestic market and developing countries will need doses of Indian vaccines
'Unit-9' for manufacturing Gabapentin & other pharma (APIs) products is expected to be complete in Q3FY22
EPS for the period at Rs. (7.57)
The company reports revenue growth of 26% and PAT growth of 21% YoY
This therapy may provide the first potential oral treatment for COVID-19, recognizing the global emergency of new SARS-CoV-2 variants
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
Winlevi, the recently added anti-acne product with a new mechanism of action and broad-based use (vs Absorica), will further boost the derma portfolio and Speciality business growth
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
Subscribe To Our Newsletter & Stay Updated